Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tuberculosis: Agents in MycPermCheck

14.01.2013
About two million people worldwide die of tuberculosis each year. There is an urgent need for new drugs and they will probably get easier to find in future – thanks to the new model MycPermCheck, which was developed at the University of Würzburg.
Tuberculosis is caused by a pathogen called Mycobacterium tuberculosis. If differs from many other types of bacteria in that it possesses a particularly thick cell wall. It is nearly impervious to foreign substances so that the pathogen is fairly drug-resistant.

"Many agents that could otherwise be highly effective fail to penetrate the thick cell wall," explains Professor Christoph Sotriffer of the Institute of Pharmacy at the University of Würzburg. Because of this barrier, many drugs do not reach their destination – the interior of the bacteria – or they arrive in such low concentrations as to be ineffective.

What gets agents through the cell wall?

Which conditions does an agent have to satisfy in order to pass easily through the cell wall of the tuberculosis pathogen? Previously, this question could not be answered by scientists. University of Würzburg pharmacologists and bioinformaticians have just come up with some first answers. Their results are published in the journal "Bioinformatics".

Christoph Sotriffer's colleagues, Benjamin Merget and David Zilian have examined 3815 substances effective against mycobacteria, comparing them with numerous ineffective or randomly selected substances. In their analyses, they identified several physico-chemical properties that are quite useful to predict whether or not a given molecule will be able to penetrate the cell wall of the pathogen. Such properties include the size of the hydrophobic area or the number of hydrogen bonding sites.

How effectiveness can be estimated

The scientists have developed the statistical model "MycPermCheck" on the basis of their findings: It can be used to estimate the probability of organic molecules with a relative molecular mass of up to approx. 500 being able to pass through the cell wall of mycobacteria and take effect in the bacterium. The model is available as a free web service on the home page of Sotriffer's study group.

"For the first time, MycPermCheck makes it possible to focus the search for agents against mycobacteria on such chemical compounds that have a high probability of being able to get inside the bacterium," the professor explains. This could be used to conduct virtual and experimental screenings more efficiently and in a more targeted way. The model can also be used to check whether any newly developed substances have the desired properties. "If this is not the case, you can try to achieve this by means of a targeted molecular design," says Sotriffer.

Why screenings are getting more effective

MycPermCheck is not a procedure with which the permeability of the bacterial cell wall can be calculated with exact precision, which point the developers emphasize. All users are advised to be aware of this. The model only increases the probability of picking out exactly the molecules that are suited to overcome the mycobacterial cell wall, when selecting from a great number of chemical compounds.

Professor Sotriffer: "Since several hundreds of thousands up to several millions of compounds are typically involved in a screening, it would already be a success if we were able to restrict the search for new agents to, say, the best ten percent of molecules that have a high probability of getting easily inside the bacterium. This would somewhat facilitate the difficult process of developing new drugs against tuberculosis."

MycPermCheck in the Internet: http://www.mycpermcheck.aksotriffer.pharmazie.uni-wuerzburg.de

The new findings were discovered at the Collaborative Research Center 630 (Recognition, Preparation and Functional Analysis of Agents against Infectious Diseases) of the University of Würzburg. The research is funded by the German Research Foundation.

Facts on tuberculosis

Tuberculosis, also known as consumption, is the most common bacterial infectious disease worldwide. More than eight million people contract the disease each year, most of them in Sub-Saharan Africa, Asia and Eastern Europe. According to the Robert Koch Institute, between 4000 and 5000 new infections were annually reported in Germany in recent years.

Mycobacterium tuberculosis bacteria in a stained electron microscopic image.

Source: Public Health Image Library / Janice Haney Carr

The pathogens mainly attack the lungs. The consequences are constant coughs with sputum, weight loss and profuse night sweats. In serious cases, the sputum is blood-stained and underweight as well as severe anemia occur. If left untreated, the disease often leads to death.

Drugs that are able to cure tuberculosis have already been available since the middle of the 20th century. However, the treatment is complicated: It takes several months and requires a combination of at least four substances. Furthermore, several strains of the pathogen have become resistant to the drugs. We don't have a lot of viable alternatives, since no new drugs have been developed for decades.

"MycPermCheck: the Mycobacterium tuberculosis permeability prediction tool for small molecules", Benjamin Merget, David Zilian, Tobias Müller, and Christoph A. Sotriffer, Bioinformatics 2013, 29 (1): 62-68; DOI: 10.1093/bioinformatics/bts641

Contact person
Prof. Dr. Christoph Sotriffer, Institute of Pharmacy and Food Chemistry, University of Würzburg, T +49 (0)931 31-85443, sotriffer@uni-wuerzburg.de

Gunnar Bartsch | idw
Further information:
http://www.uni-wuerzburg.de

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>